Acasă › Leucemie limfatică cronică › Florida

Studii clinice pentru Leucemie limfatică cronică în Florida

34 studii pentru Leucemie limfatică cronică caută participanți în Florida.

Orașe în Florida

Text oficial al studiului (în engleză)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
și încă 9

În curs de recrutareFaza 3

Vârste de 65 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mount Sinai Comprehensive Cancer Center at Aventura, Aventura
Schulze Family Foundation Cancer Clinic - Bonita Health Center, Bonita Springs
Morton Plant Hospital, Clearwater
și încă 11

În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți

Vârste de la 40 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT05334069

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Study Site 102, St. Petersburg

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 1 oct. 2026 · NCT07582432

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Holy Cross Hospital, Fort Lauderdale

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT04269902

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

GC2202 Study Site 103, St. Petersburg

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Cleveland Clinic Florida, Weston

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Mayo Clinic Jacksonville, Jacksonville
Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
Tampa General Hospital Cancer Institute, Tampa

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Mayo Clinic Jacksonville, Jacksonville
Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
Moffitt Cancer Center, Tampa

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07277231

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Florida Oncology and Hematology, Fort Myers
Baptist Md Anderson Cancer Center, Jacksonville
Cleveland Clinic Florida, Weston

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT06846671

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Moffitt Cancer Center, Tampa

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT06697184

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic Jacksonville, Jacksonville
Cancer Specialists of North Florida, Jacksonville
Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT06973187

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Clermont Oncology Center ( Site 5430), Clermont
Memorial Hospital West ( Site 5410), Pembroke Pines

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT05947851

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Lynn Cancer Center at Boca Raton Regional Hospital ( Site 0063), Boca Raton
Clermont Oncology Center ( Site 0046), Clermont
Florida Cancer Specialists - South ( Site 7001), Fort Myers
și încă 1

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT06136559

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Cancer Specialists, LLC, Jacksonville

În curs de recrutareFaza 4

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07218341

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

SSAK Partners, Coral Springs
Mayo Clinic - Jacksonville, Jacksonville

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 21 sept. 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

University of Miami, Coral Gables
Florida Cancer Specialists, Sarasota

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 sept. 2026 · NCT07221500

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

H. Lee Moffitt Cancer Center, Tampa

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 8 sept. 2026 · NCT03666000

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Mayo Clinic, Jacksonville
Moffitt Cancer Center, Tampa

În curs de recrutareFaza 1/2

Vârste de 12 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT04588922

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

University of Miami, Coral Gables

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 aug. 2026 · NCT07520006

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Florida Cancer Specialists, Fort Myers
Cancer Specialists of North Florida -St Augustine, Saint Augustine
Florida Cancer Specialists East, West Palm Beach

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 aug. 2026 · NCT05254743

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Mayo Clinic, Clinical Trials Referral Office, Jacksonville

În curs de recrutareFaza 1/2

Vârste de la 13 la 90 · Toate sexele · Actualizat 6 aug. 2026 · NCT06533579

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

University of Miami, Miami
Florida Cancer Specialists, Sarasota

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 2 iul. 2026 · NCT05131022

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Mt Sinai Comprehensive Cancer Center, Miami Beach

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 12 iun. 2026 · NCT07271667

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 19 mai 2026 · NCT06588478

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

ASCLEPES Research Centers, Weeki Wachee

În curs de recrutareFaza 1/2

Vârste de la 12 la 95 · Toate sexele · Actualizat 15 apr. 2026 · NCT04329728

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Malcolm Randall V.A. Medical Center /ID# 267825, Gainesville
Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713, Jacksonville
Mid Florida Hematology And Oncology Center /ID# 269159, Orange City
și încă 1

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 9 apr. 2026 · NCT06428019

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

Moffitt Cancer Center, Tampa

În curs de recrutareStudiu observațional

Vârste de 18 ani și peste · Toate sexele · Actualizat 1 apr. 2026 · NCT07030400

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 13 mar. 2026 · NCT07218510

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Sylvester Comprehensive Cancer Center, Miami
Florida Cancer Specialists, Sarasota

În curs de recrutareFaza 4

Vârste de 18 ani și peste · Toate sexele · Actualizat 2 mar. 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Cancer Specialists, LLC, Jacksonville
Sylvester Comprehensive Cancer Center, Miami
Florida Cancer Specialists, Sarasota

În curs de recrutareFaza 4

Vârste de 18 ani și peste · Toate sexele · Actualizat 2 mar. 2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

Napa Research, Pompano Beach

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 13 feb. 2026 · NCT05544019

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Mayo Clinic in Florida, Jacksonville

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 13 feb. 2026 · NCT06191887

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Mount Sinai Comprehensive Cancer Center, Miami Beach
Moffitt Cancer Center, Tampa

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 10 dec. 2025 · NCT05602363

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Florida Cancer Specialists, Sarasota

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 2 oct. 2025 · NCT05780034

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.